{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:31:46Z","timestamp":1792801906593,"version":"4.5.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T00:00:00Z","timestamp":1682380800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T00:00:00Z","timestamp":1682380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"KRIBB Research Initiative Program","award":["KGM5242221"],"award-info":[{"award-number":["KGM5242221"]}]},{"name":"National Research Foundation of Korea Grant funded by the Korean Government","award":["2019R1A2B5B01069444"],"award-info":[{"award-number":["2019R1A2B5B01069444"]}],"id":[{"id":"https:\/\/ror.org\/013aysd81","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Atopic dermatitis (AD) is a chronic inflammatory skin disease that affects from children to adults widely, presenting symptoms such as pruritus, erythema, scaling, and dryness. Lupeol, a pentacyclic triterpenoid, has anti-inflammatory and antimicrobial activities. Based on these properties, the therapeutic effects of lupeol on skin disorders have been actively studied. In the present study, we aimed to determine the effectiveness of lupeol on AD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We utilized tumor necrosis factor (TNF)-\u03b1\/interferon (IFN)-\u03b3-stimulated keratinocytes and 2, 4-dinitrochlorobenzene\/\n                      <jats:italic>Dermatophagoides farinae<\/jats:italic>\n                      extract (DFE)-induced AD mice to confirm the action.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Lupeol inhibited TNF-\u03b1\/IFN-\u03b3-stimulated keratinocytes activation by reducing the expressions of pro-inflammatory cytokines and chemokines which are mediated by the activation of signaling molecules such as signal transducer and activator of transcription 1, mitogen-activated protein kinases (p38 and ERK), and nuclear factor-\u03baB. Oral administration of lupeol suppressed epidermal and dermal thickening and immune cell infiltration in ear tissue. Immunoglobulin (Ig) E (total and DFE-specific) and IgG2a levels in serum were also reduced by lupeol. The gene expression and protein secretion of T helper (Th) 2 cytokines, Th1 cytokines, and pro-inflammatory cytokine in ear tissue were decreased by lupeol.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These results suggest that lupeol has inhibitory effects on AD-related responses. Therefore, lupeol could be a promising therapeutic agent for AD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40360-023-00668-9","type":"journal-article","created":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T08:06:47Z","timestamp":1682410007000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Lupeol alleviates atopic dermatitis-like skin inflammation in 2,4-dinitrochlorobenzene\/Dermatophagoides farinae extract-induced mice"],"prefix":"10.1186","volume":"24","author":[{"given":"Sojung","family":"Bae","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na-Hee","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Ae","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byungheon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong Hyun","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soyoung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,25]]},"reference":[{"issue":"Suppl 1","key":"668_CR1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1159\/000370220","volume":"66","author":"S Nutten","year":"2015","unstructured":"Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab. 2015;66(Suppl 1):8\u201316.","journal-title":"Ann Nutr Metab"},{"issue":"6","key":"668_CR2","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1001\/jamadermatol.2013.10271","volume":"150","author":"JS Margolis","year":"2014","unstructured":"Margolis JS, Abuabara K, Bilker W, Hoffstad O, Margolis DJ. Persistence of mild to moderate atopic dermatitis. JAMA Dermatol. 2014;150(6):593\u2013600.","journal-title":"JAMA Dermatol"},{"issue":"6","key":"668_CR3","doi-asserted-by":"publisher","first-page":"662","DOI":"10.4103\/0019-5154.193679","volume":"61","author":"AJ Kanwar","year":"2016","unstructured":"Kanwar AJ. Adult-onset atopic dermatitis. Indian J Dermatol. 2016;61(6):662\u20133.","journal-title":"Indian J Dermatol"},{"issue":"1","key":"668_CR4","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jid.2016.07.012","volume":"137","author":"AM Drucker","year":"2017","unstructured":"Drucker AM, Wang AR, Li WQ, Sevetson E, Block JK, Qureshi AA. The burden of atopic dermatitis: summary of a report for the national eczema association. J Invest Dermatol. 2017;137(1):26\u201330.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"668_CR5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/all.12268","volume":"69","author":"SC Dharmage","year":"2014","unstructured":"Dharmage SC, Lowe AJ, Matheson MC, Burgess JA, Allen KJ, Abramson MJ. Atopic dermatitis and the atopic march revisited. Allergy. 2014;69(1):17\u201327.","journal-title":"Allergy"},{"issue":"8","key":"668_CR6","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.3390\/ijms21082867","volume":"21","author":"G Yang","year":"2020","unstructured":"Yang G, Seok JK, Kang HC, Cho YY, Lee HS, Lee JY. Skin barrier abnormalities and immune dysfunction in atopic dermatitis. Int J Mol Sci. 2020;21(8):2867.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"668_CR7","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/j.jaci.2020.02.021","volume":"145","author":"DYM Leung","year":"2020","unstructured":"Leung DYM, Berdyshev E, Goleva E. Cutaneous barrier dysfunction in allergic diseases. J Allergy Clin Immunol. 2020;145(6):1485\u201397.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"668_CR8","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1007\/s12016-018-8693-0","volume":"57","author":"JD Miller","year":"2019","unstructured":"Miller JD. The role of dust mites in allergy. Clin Rev Allergy Immunol. 2019;57(3):312\u201329.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"3","key":"668_CR9","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/cei.13575","volume":"204","author":"P Chieosilapatham","year":"2021","unstructured":"Chieosilapatham P, Kiatsurayanon C, Umehara Y, Trujillo-Paez JV, Peng G, Yue H, et al. Keratinocytes: innate immune cells in atopic dermatitis. Clin Exp Immunol. 2021;204(3):296\u2013309.","journal-title":"Clin Exp Immunol"},{"issue":"20","key":"668_CR10","doi-asserted-by":"publisher","first-page":"e142067","DOI":"10.1172\/jci.insight.142067","volume":"5","author":"Y Jiang","year":"2020","unstructured":"Jiang Y, Tsoi LC, Billi AC, Ward NL, Harms PW, Zeng C, et al. Cytokinocytes: the diverse contribution of keratinocytes to immune responses in skin. JCI Insight. 2020;5(20):e142067.","journal-title":"JCI Insight"},{"issue":"7","key":"668_CR11","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1111\/all.14318","volume":"75","author":"CA Akdis","year":"2020","unstructured":"Akdis CA, Arkwright PD, Bruggen MC, Busse W, Gadina M, Guttman-Yassky E, et al. Type 2 immunity in the skin and lungs. Allergy. 2020;75(7):1582\u2013605.","journal-title":"Allergy"},{"issue":"3 Suppl 2","key":"668_CR12","doi-asserted-by":"publisher","first-page":"R7","DOI":"10.1016\/j.jaci.2009.07.012","volume":"124","author":"MD Howell","year":"2009","unstructured":"Howell MD, Kim BE, Gao P, Grant AV, Boguniewicz M, DeBenedetto A, et al. Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol. 2009;124(3 Suppl 2):R7\u201312.","journal-title":"J Allergy Clin Immunol"},{"issue":"8888","key":"668_CR13","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0140-6736(94)90879-6","volume":"343","author":"M Grewe","year":"1994","unstructured":"Grewe M, Gyufko K, Schopf E, Krutmann J. Lesional expression of IFN-\u03b3 in atopic eczema. Lancet. 1994;343(8888):25\u20136.","journal-title":"Lancet"},{"issue":"5","key":"668_CR14","doi-asserted-by":"publisher","first-page":"418","DOI":"10.37349\/ei.2021.00028","volume":"1","author":"X Ni","year":"2021","unstructured":"Ni X, Lai Y. Crosstalk between keratinocytes and immune cells in inflammatory skin diseases. Explor Immunol. 2021;1(5):418\u201331.","journal-title":"Explor Immunol"},{"issue":"3","key":"668_CR15","doi-asserted-by":"publisher","first-page":"181","DOI":"10.4168\/aair.2016.8.3.181","volume":"8","author":"JH Lee","year":"2016","unstructured":"Lee JH, Son SW, Cho SH. A comprehensive review of the treatment of atopic eczema. Allergy Asthma Immunol Res. 2016;8(3):181\u201390.","journal-title":"Allergy Asthma Immunol Res"},{"issue":"4","key":"668_CR16","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.jaad.2017.09.074","volume":"78","author":"SH Yu","year":"2018","unstructured":"Yu SH, Drucker AM, Lebwohl M, Silverberg JI. A systematic review of the safety and efficacy of systemic corticosteroids in atopic dermatitis. J Am Acad Dermatol. 2018;78(4):733\u201340.","journal-title":"J Am Acad Dermatol"},{"issue":"7\u20138","key":"668_CR17","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.lfs.2010.11.020","volume":"88","author":"HR Siddique","year":"2011","unstructured":"Siddique HR, Saleem M. Beneficial health effects of lupeol triterpene: a review of preclinical studies. Life Sci. 2011;88(7\u20138):285\u201393.","journal-title":"Life Sci"},{"key":"668_CR18","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/978-3-319-41342-6_7","volume":"929","author":"FS Tsai","year":"2016","unstructured":"Tsai FS, Lin LW, Wu CR. Lupeol and its role in chronic diseases. Adv Exp Med Biol. 2016;929:145\u201375.","journal-title":"Adv Exp Med Biol"},{"key":"668_CR19","doi-asserted-by":"publisher","first-page":"105373","DOI":"10.1016\/j.phrs.2020.105373","volume":"164","author":"K Liu","year":"2021","unstructured":"Liu K, Zhang X, Xie L, Deng M, Chen H, Song J, et al. Lupeol and its derivatives as anticancer and anti-inflammatory agents: molecular mechanisms and therapeutic efficacy. Pharmacol Res. 2021;164:105373.","journal-title":"Pharmacol Res"},{"issue":"11","key":"668_CR20","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1211\/0022357011777909","volume":"53","author":"MA Fernandez","year":"2001","unstructured":"Fernandez MA, de las Heras B, Garcia MD, Saenz MT, Villar A. New insights into the mechanism of action of the anti-inflammatory triterpene lupeol. J Pharm Pharmacol. 2001;53(11):1533\u20139.","journal-title":"J Pharm Pharmacol"},{"issue":"9","key":"668_CR21","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/j.intimp.2008.04.011","volume":"8","author":"JF Vasconcelos","year":"2008","unstructured":"Vasconcelos JF, Teixeira MM, Barbosa-Filho JM, Lucio AS, Almeida JR, de Queiroz LP, et al. The triterpenoid lupeol attenuates allergic airway inflammation in a murine model. Int Immunopharmacol. 2008;8(9):1216\u201321.","journal-title":"Int Immunopharmacol"},{"issue":"6","key":"668_CR22","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1038\/jid.2015.29","volume":"135","author":"HH Kwon","year":"2015","unstructured":"Kwon HH, Yoon JY, Park SY, Min S, Kim YI, Park JY, et al. Activity-guided purification identifies lupeol, a pentacyclic triterpene, as a therapeutic agent multiple pathogenic factors of acne. J Invest Dermatol. 2015;135(6):1491\u2013500.","journal-title":"J Invest Dermatol"},{"key":"668_CR23","doi-asserted-by":"publisher","first-page":"3182627","DOI":"10.1155\/2019\/3182627","volume":"2019","author":"FP Beserra","year":"2019","unstructured":"Beserra FP, Vieira AJ, Gushiken LFS, de Souza EO, Hussni MF, Hussni CA, et al. Lupeol, a dietary triterpene, enhances wound healing in streptozotocin-induced hyperglycemic rats with modulatory effects on inflammation, oxidative stress, and angiogenesis. Oxid Med Cell Longev. 2019;2019:3182627.","journal-title":"Oxid Med Cell Longev"},{"issue":"7","key":"668_CR24","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1158\/1078-0432.CCR-07-4413","volume":"14","author":"M Saleem","year":"2008","unstructured":"Saleem M, Maddodi N, Abu Zaid M, Khan N, bin Hafeez B, Asim M, et al. Lupeol inhibits growth of highly aggressive human metastatic melanoma cells in vitro and in vivo by inducing apoptosis. Clin Cancer Res. 2008;14(7):2119\u201327.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"668_CR25","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1002\/pro.3519","volume":"27","author":"R Morris","year":"2018","unstructured":"Morris R, Kershaw NJ, Babon JJ. The molecular details of cytokine signaling via the JAK\/STAT pathway. Protein Sci. 2018;27(12):1984\u20132009.","journal-title":"Protein Sci"},{"issue":"1\u20132","key":"668_CR26","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.bbapap.2005.08.017","volume":"1754","author":"B Kaminska","year":"2005","unstructured":"Kaminska B. MAPK signalling pathways as molecular targets for anti-inflammatory therapy\u2013from molecular mechanisms to therapeutic benefits. Biochim Biophys Acta. 2005;1754(1\u20132):253\u201362.","journal-title":"Biochim Biophys Acta"},{"key":"668_CR27","doi-asserted-by":"publisher","first-page":"17023","DOI":"10.1038\/sigtrans.2017.23","volume":"2","author":"T Liu","year":"2017","unstructured":"Liu T, Zhang L, Joo D, Sun SC. NF-\u03baB signaling in inflammation. Signal Transduct Target Ther. 2017;2:17023.","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"668_CR28","doi-asserted-by":"publisher","first-page":"e2021146","DOI":"10.5826\/dpc.1104a146","volume":"11","author":"A Raimondo","year":"2021","unstructured":"Raimondo A, Lembo S. Atopic dermatitis: epidemiology and clinical phenotypes. Dermatol Pract Concept. 2021;11(4):e2021146.","journal-title":"Dermatol Pract Concept"},{"key":"668_CR29","doi-asserted-by":"publisher","first-page":"204062232110029","DOI":"10.1177\/20406223211002979","volume":"12","author":"G Girolomoni","year":"2021","unstructured":"Girolomoni G, de Bruin-Weller M, Aoki V, Kabashima K, Deleuran M, Puig L, et al. Nomenclature and clinical phenotypes of atopic dermatitis. Ther Adv Chronic Dis. 2021;12:20406223211002979.","journal-title":"Ther Adv Chronic Dis"},{"issue":"5","key":"668_CR30","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1046\/j.1365-2133.2001.04456.x","volume":"145","author":"P Kiehl","year":"2001","unstructured":"Kiehl P, Falkenberg K, Vogelbruch M, Kapp A. Tissue eosinophilia in acute and chronic atopic dermatitis: a morphometric approach using quantitative image analysis of immunostaining. Br J Dermatol. 2001;145(5):720\u20139.","journal-title":"Br J Dermatol"},{"issue":"6","key":"668_CR31","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.coi.2009.09.006","volume":"21","author":"T Kawakami","year":"2009","unstructured":"Kawakami T, Ando T, Kimura M, Wilson BS, Kawakami Y. Mast cells in atopic dermatitis. Curr Opin Immunol. 2009;21(6):666\u201378.","journal-title":"Curr Opin Immunol"},{"issue":"8","key":"668_CR32","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1111\/all.12184","volume":"68","author":"K Eyerich","year":"2013","unstructured":"Eyerich K, Novak N. Immunology of atopic eczema: overcoming the Th1\/Th2 paradigm. Allergy. 2013;68(8):974\u201382.","journal-title":"Allergy"},{"issue":"2","key":"668_CR33","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.alit.2019.08.013","volume":"69","author":"K Sugita","year":"2020","unstructured":"Sugita K, Akdis CA. Recent developments and advances in atopic dermatitis and food allergy. Allergol Int. 2020;69(2):204\u201314.","journal-title":"Allergol Int"},{"issue":"2","key":"668_CR34","doi-asserted-by":"publisher","first-page":"120","DOI":"10.4161\/self.2.2.16939","volume":"2","author":"ES Fedenko","year":"2011","unstructured":"Fedenko ES, Elisyutina OG, Filimonova TM, Boldyreva MN, Burmenskaya OV, Rebrova OY, et al. Cytokine gene expression in the skin and peripheral blood of atopic dermatitis patients and healthy individuals. Self Nonself. 2011;2(2):120\u20134.","journal-title":"Self Nonself"},{"issue":"3","key":"668_CR35","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.anai.2018.07.006","volume":"121","author":"JI Silverberg","year":"2018","unstructured":"Silverberg JI, Gelfand JM, Margolis DJ, Boguniewicz M, Fonacier L, Grayson MH, et al. Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study. Ann Allergy Asthma Immunol. 2018;121(3):340\u20137.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"668_CR36","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s40266-020-00750-5","volume":"37","author":"R Tanei","year":"2020","unstructured":"Tanei R. Atopic dermatitis in older adults: a review of treatment options. Drugs Aging. 2020;37(3):149\u201360.","journal-title":"Drugs Aging"},{"key":"668_CR37","doi-asserted-by":"publisher","first-page":"111741","DOI":"10.1016\/j.biopha.2021.111741","volume":"140","author":"S Wu","year":"2021","unstructured":"Wu S, Pang Y, He Y, Zhang X, Peng L, Guo J, et al. A comprehensive review of natural products against atopic dermatitis: flavonoids, alkaloids, terpenes, glycosides and other compounds. Biomed Pharmacother. 2021;140:111741.","journal-title":"Biomed Pharmacother"},{"issue":"6","key":"668_CR38","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s40495-020-00244-3","volume":"6","author":"R Sharma","year":"2020","unstructured":"Sharma R, Prajapati PK. Predictive, preventive and personalized medicine: leads from ayurvedic concept of Prakriti (Human constitution). Curr Pharmacol Rep. 2020;6(6):441\u201350.","journal-title":"Curr Pharmacol Rep"},{"issue":"2","key":"668_CR39","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.canlet.2009.04.033","volume":"285","author":"M Saleem","year":"2009","unstructured":"Saleem M. Lupeol, a novel anti-inflammatory and anti-cancer dietary triterpene. Cancer Lett. 2009;285(2):109\u201315.","journal-title":"Cancer Lett"},{"issue":"3","key":"668_CR40","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1067\/mai.2001.113237","volume":"107","author":"T Kakinuma","year":"2001","unstructured":"Kakinuma T, Nakamura K, Wakugawa M, Mitsui H, Tada Y, Saeki H, et al. Thymus and activation-regulated chemokine in atopic dermatitis: serum thymus and activation-regulated chemokine level is closely related with disease activity. J Allergy Clin Immunol. 2001;107(3):535\u201341.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"668_CR41","first-page":"e24137","volume":"2","author":"L Bao","year":"2013","unstructured":"Bao L, Zhang H, Chan LS. The involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitis. JAKSTAT. 2013;2(3):e24137.","journal-title":"JAKSTAT"},{"issue":"7","key":"668_CR42","doi-asserted-by":"publisher","first-page":"3467","DOI":"10.3390\/ijms23073467","volume":"23","author":"N Zeze","year":"2022","unstructured":"Zeze N, Kido-Nakahara M, Tsuji G, Maehara E, Sato Y, Sakai S, et al. Role of ERK pathway in the pathogenesis of atopic dermatitis and its potential as a therapeutic target. Int J Mol Sci. 2022;23(7):3467.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"668_CR43","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1038\/sj.jid.5700603","volume":"127","author":"A Tanaka","year":"2007","unstructured":"Tanaka A, Muto S, Jung K, Itai A, Matsuda H. Topical application with a new NF-\u03baB inhibitor improves atopic dermatitis in NC\/NgaTnd mice. J Invest Dermatol. 2007;127(4):855\u201363.","journal-title":"J Invest Dermatol"},{"issue":"15","key":"668_CR44","doi-asserted-by":"publisher","first-page":"4409","DOI":"10.3390\/molecules26154409","volume":"26","author":"J Kang","year":"2021","unstructured":"Kang J, Lee S, Kim N, Dhakal H, Kwon TK, Kim EN, et al. Gomisin M2 ameliorates atopic dermatitis-like skin lesions via inhibition of STAT1 and NF-\u03baB activation in 2,4-dinitrochlorobenzene\/Dermatophagoides farinae extract-induced BALB\/c mice. Molecules. 2021;26(15):4409.","journal-title":"Molecules"},{"key":"668_CR45","doi-asserted-by":"publisher","first-page":"110466","DOI":"10.1016\/j.biopha.2020.110466","volume":"129","author":"JS Lim","year":"2020","unstructured":"Lim JS, Kim JY, Lee S, Choi JK, Kim EN, Choi YA, et al. Bakuchicin attenuates atopic skin inflammation. Biomed Pharmacother. 2020;129:110466.","journal-title":"Biomed Pharmacother"},{"issue":"12","key":"668_CR46","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1038\/nri.2017.95","volume":"17","author":"PF Weller","year":"2017","unstructured":"Weller PF, Spencer LA. Functions of tissue-resident eosinophils. Nat Rev Immunol. 2017;17(12):746\u201360.","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"668_CR47","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/nm.2755","volume":"18","author":"SJ Galli","year":"2012","unstructured":"Galli SJ, Tsai M. IgE and mast cells in allergic disease. Nat Med. 2012;18(5):693\u2013704.","journal-title":"Nat Med"},{"issue":"1","key":"668_CR48","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.cyto.2014.09.011","volume":"74","author":"I Raphael","year":"2015","unstructured":"Raphael I, Nalawade S, Eagar TN, Forsthuber TG. T cell subsets and their signature cytokines in autoimmune and inflammatory diseases. Cytokine. 2015;74(1):5\u201317.","journal-title":"Cytokine"},{"key":"668_CR49","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3389\/fimmu.2015.00353","volume":"6","author":"T Biedermann","year":"2015","unstructured":"Biedermann T, Skabytska Y, Kaesler S, Volz T. Regulation of T cell immunity in atopic dermatitis by microbes: the yin and yang of cutaneous inflammation. Front Immunol. 2015;6:353.","journal-title":"Front Immunol"},{"issue":"5","key":"668_CR50","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1080\/1744666X.2017.1298443","volume":"13","author":"NA Gandhi","year":"2017","unstructured":"Gandhi NA, Pirozzi G, Graham NMH. Commonality of the IL-4\/IL-13 pathway in atopic diseases. Expert Rev Clin Immunol. 2017;13(5):425\u201337.","journal-title":"Expert Rev Clin Immunol"},{"key":"668_CR51","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.3389\/fphys.2019.01514","volume":"10","author":"C Pelaia","year":"2019","unstructured":"Pelaia C, Paoletti G, Puggioni F, Racca F, Pelaia G, Canonica GW, et al. Interleukin-5 in the pathophysiology of severe asthma. Front Physiol. 2019;10:1514.","journal-title":"Front Physiol"},{"key":"668_CR52","doi-asserted-by":"crossref","unstructured":"Biedermann T, Rocken M, Carballido JM. Th1 and Th2 lymphocyte development and regulation of Th cell-mediated immune responses of the skin. J Investig Dermatol Symp Proc. 2004;9(1):5\u201314.","DOI":"10.1111\/j.1087-0024.2004.00829.x"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-023-00668-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-023-00668-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-023-00668-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T09:08:01Z","timestamp":1682413681000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-023-00668-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,25]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["668"],"URL":"https:\/\/doi.org\/10.1186\/s40360-023-00668-9","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,25]]},"assertion":[{"value":"24 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was carried out in accordance with ARRIVE guidelines and Public Health Service Policy on the Humane Care and Use of Laboratory Animals guidelines. The experiment was approved by the Institutional Animal Care and Use Committee of Kyungpook National University (IRB # 2021-0073).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"27"}}